Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER versus PANWARFIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER versus PANWARFIN.
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER vs PANWARFIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and factor Xa. This inhibits fibrin formation and prevents clot propagation. Dextrose 5% provides a source of calories and fluid.
Anticoagulant that inhibits vitamin K epoxide reductase, thereby decreasing hepatic synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X.
For therapeutic anticoagulation in adults, heparin is administered intravenously as an initial bolus of 80 units/kg followed by a continuous infusion of 18 units/kg/hour, with dose adjustment based on activated partial thromboplastin time (aPTT) targeting 1.5-2.5 times control. The concentration of heparin sodium 25,000 units and dextrose 5% in plastic container is typically used for continuous infusion at a rate calculated to deliver the prescribed units per hour.
5 mg orally once daily, adjusted to maintain INR 2-3.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (dose-dependent, prolonged with higher doses due to saturable clearance). In hepatic or renal impairment: 1.5-3 hours. Clinical context: Twice-daily dosing may not maintain therapeutic levels; monitoring aPTT is essential.
Terminal elimination half-life is 20-60 hours (mean ~40 hours). Clinically, the longer half-life allows for once-daily dosing and steady-state is achieved in 5-7 days; anticoagulant effect may persist for 2-5 days after discontinuation due to depletion of vitamin K-dependent clotting factors.
Renal: 40-50% as unchanged heparin (saturable); reticuloendothelial system: partial metabolism to uroheparin (less active); fecal: minimal (<5%).
Primarily renal as inactive metabolites; 60-92% of a dose is excreted in urine, with about 50% as the 7-hydroxywarfarin metabolite and the remainder as other metabolites. Biliary/fecal elimination accounts for approximately 10-20%.
Category A/B
Category C
Anticoagulant
Anticoagulant